Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes
SM Hunter, MS Anglesio, GL Ryland, R Sharma, YE Chiew, SM Rowley, MA Doyle, J Li, CB Gilks, P Moss, PE Allan, AN Stephens, DG Huntsman, A deFazio, DD Bowtell, G Australian Ovarian Cancer Study, KL Gorringe, IG Campbell
Oncotarget | Impact Journals | Published : 2015
Low grade serous ovarian tumours are a rare and under-characterised histological subtype of epithelial ovarian tumours, with little known of the molecular drivers and facilitators of tumorigenesis beyond classic oncogenic RAS/RAF mutations. With a move towards targeted therapies due to the chemoresistant nature of this subtype, it is pertinent to more fully characterise the genetic events driving this tumour type, some of which may influence response to therapy and/or development of drug resistance. We performed genome-wide high-resolution genomic copy number analysis (Affymetrix SNP6.0) and mutation hotspot screening (KRAS, BRAF, NRAS, HRAS, ERBB2 and TP53) to compare a large cohort of ovar..View full abstract
Related Projects (3)
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by U.S. Army Medical Research and Materiel Command
This work was supported by a grant (ID 628630) from the National Health and Medical Research Council of Australia (NHMRC), the Victorian Breast Cancer Research Consortium (VBCRC) and the Emer Casey Foundation. The AOCS was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Tasmania, The Cancer Foundation of Western Australia and the National Health and Medical Research Council of Australia (NHMRC; IDs 400281 and 400413). A deFazio is funded by the University of Sydney Cancer Research Fund and the Cancer Institute NSW through the Sydney-West Translational Cancer Research Centre. A Stephens is supported by a grant from the Ovarian Cancer Research Foundation.